AU2017361257B2 - Crystalline forms of a MAGL inhibitor - Google Patents

Crystalline forms of a MAGL inhibitor Download PDF

Info

Publication number
AU2017361257B2
AU2017361257B2 AU2017361257A AU2017361257A AU2017361257B2 AU 2017361257 B2 AU2017361257 B2 AU 2017361257B2 AU 2017361257 A AU2017361257 A AU 2017361257A AU 2017361257 A AU2017361257 A AU 2017361257A AU 2017361257 B2 AU2017361257 B2 AU 2017361257B2
Authority
AU
Australia
Prior art keywords
compound
theta
crystalline
hexafluoropropan
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017361257A
Other languages
English (en)
Other versions
AU2017361257A1 (en
Inventor
Channing Rodney Beals
Jacqueline Lorayne BLANKMAN
Cheryl A. Grice
Kurt G. GRIMM
Todd K. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2017361257A1 publication Critical patent/AU2017361257A1/en
Assigned to LUNDBECK LA JOLLA RESEARCH CENTER, INC. reassignment LUNDBECK LA JOLLA RESEARCH CENTER, INC. Request for Assignment Assignors: ABIDE THERAPEUTICS, INC.
Assigned to H. LUNDBECK A/S. reassignment H. LUNDBECK A/S. Request for Assignment Assignors: LUNDBECK LA JOLLA RESEARCH CENTER, INC.
Application granted granted Critical
Publication of AU2017361257B2 publication Critical patent/AU2017361257B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017361257A 2016-11-16 2017-11-15 Crystalline forms of a MAGL inhibitor Ceased AU2017361257B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423126P 2016-11-16 2016-11-16
US62/423,126 2016-11-16
PCT/US2017/061875 WO2018093953A1 (en) 2016-11-16 2017-11-15 Crystalline forms of a magl inhibitor

Publications (2)

Publication Number Publication Date
AU2017361257A1 AU2017361257A1 (en) 2019-05-30
AU2017361257B2 true AU2017361257B2 (en) 2022-02-10

Family

ID=62145805

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017361257A Ceased AU2017361257B2 (en) 2016-11-16 2017-11-15 Crystalline forms of a MAGL inhibitor

Country Status (38)

Country Link
US (2) US11142517B2 (cg-RX-API-DMAC7.html)
EP (2) EP3541807B1 (cg-RX-API-DMAC7.html)
JP (2) JP7042548B2 (cg-RX-API-DMAC7.html)
KR (1) KR102508739B1 (cg-RX-API-DMAC7.html)
CN (2) CN115093382A (cg-RX-API-DMAC7.html)
AU (1) AU2017361257B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019010003A2 (cg-RX-API-DMAC7.html)
CA (1) CA3043610A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001340A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019005045A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190242A (cg-RX-API-DMAC7.html)
CY (1) CY1124870T1 (cg-RX-API-DMAC7.html)
DK (1) DK3541807T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2019000120A (cg-RX-API-DMAC7.html)
EA (1) EA201991086A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19035171A (cg-RX-API-DMAC7.html)
ES (2) ES2966939T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20237559B (cg-RX-API-DMAC7.html)
HR (2) HRP20211863T1 (cg-RX-API-DMAC7.html)
HU (2) HUE064559T2 (cg-RX-API-DMAC7.html)
IL (1) IL266548A (cg-RX-API-DMAC7.html)
JO (1) JOP20190109B1 (cg-RX-API-DMAC7.html)
LT (1) LT3541807T (cg-RX-API-DMAC7.html)
MA (2) MA46866B1 (cg-RX-API-DMAC7.html)
MX (2) MX389459B (cg-RX-API-DMAC7.html)
MY (1) MY199386A (cg-RX-API-DMAC7.html)
NI (1) NI201900053A (cg-RX-API-DMAC7.html)
PE (1) PE20191239A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501068A1 (cg-RX-API-DMAC7.html)
PL (2) PL3964503T3 (cg-RX-API-DMAC7.html)
PT (1) PT3541807T (cg-RX-API-DMAC7.html)
RS (2) RS65016B1 (cg-RX-API-DMAC7.html)
SI (1) SI3541807T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100675T1 (cg-RX-API-DMAC7.html)
TN (1) TN2019000151A1 (cg-RX-API-DMAC7.html)
UA (1) UA124585C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018093953A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903093B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028085B1 (ru) 2012-01-06 2017-10-31 Эбайд Терапьютикс, Инк. Карбаматные соединения и их применение
WO2016183097A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
MX393241B (es) 2016-11-16 2025-03-24 H Lundbeck As Formulaciones farmaceuticas.
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
RS65016B1 (sr) 2016-11-16 2024-01-31 H Lundbeck As Kristalni oblik magl inhibitora
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
UA124990C2 (uk) 2017-05-23 2021-12-22 Луннбек Ла-Холья Рісьоч Сенте, Інк. Інгібітори magl на основі піразолу
CN111050765B (zh) 2017-08-29 2024-01-02 H.隆德贝克有限公司 螺环化合物及其制造和使用方法
SG11202011228TA (en) * 2018-05-15 2020-12-30 Lundbeck La Jolla Research Center Inc Magl inhibitors
BR112021000109A2 (pt) * 2018-07-19 2021-03-30 Pfizer Inc. Compostos espiro heterocíclicos como inibidores de magl
UA127629C2 (uk) 2018-08-13 2023-11-08 Ф. Хоффманн-Ля Рош Аг Нові гетероциклічні сполуки як інгібітори моноацилгліцеролліпази
US20220110933A1 (en) * 2019-01-25 2022-04-14 H. Lundbeck A/S Methods of treating disease with magl inhibitors
AU2020383502A1 (en) * 2019-11-15 2022-06-30 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor
CA3175210A1 (en) * 2020-04-21 2021-10-28 Cheryl A. Grice Synthesis of a monoacylglycerol lipase inhibitor
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
KR20240128870A (ko) 2021-12-29 2024-08-27 싸이 테라퓨틱스, 인크. 모노아실글리세롤 리파아제(magl) 억제
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
CN117665187B (zh) * 2023-11-23 2024-08-16 宁波大红鹰药业股份有限公司 一种舒林酸中间体杂质的测定方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150018335A1 (en) * 2012-01-06 2015-01-15 Abide Therapeutics, Inc Carbamate compounds and of making and using same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
CA2108575C (en) 1991-04-16 2002-10-22 Kouichi Nakamichi Method of manufacturing solid dispersion
ES2149781T3 (es) 1991-11-22 2000-11-16 Procter & Gamble Pharma Composiciones de risedronato de liberacion retardada.
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
SK7652003A3 (en) 2000-12-18 2003-12-02 Novartis Ag Therapeutic combination of amlodipine and benazepril
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
MXPA04008073A (es) 2002-02-20 2004-11-26 Abbott Lab Compuestos azabiciclicos fusionados que inhiben el receptor de subtipo 1 (vr1) del receptor de vainilloide.
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1855655A2 (en) 2005-02-25 2007-11-21 F. Hoffmann-Roche AG Tablets with improved drug substance dispersibility
EA017290B1 (ru) 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед Композиции на основе ганаксолона
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN101530399B (zh) 2009-04-15 2011-01-26 江苏中兴药业有限公司 一种水飞蓟宾固体自乳化片
MX2014011134A (es) 2012-03-19 2014-12-10 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos.
US9321750B2 (en) 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
BR112015009913B1 (pt) 2012-11-02 2023-04-11 Vertex Pharmaceuticals Incorporated Comprimido compreendendo composto cristalino e dispersão sólida de composto substancialmente amorfo, seu processo de preparação, kit e método de preparação de um grânulo compreendendo composto cristalino e dispersão sólida de composto substancialmente amorfo
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター，インク． ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN103893258B (zh) 2013-12-05 2017-09-29 人福医药集团股份公司 含有广金钱草总黄酮的口服固体制剂及其应用
EP3134092B1 (en) 2014-04-21 2020-06-24 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
WO2015179559A2 (en) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
CN107660199B (zh) 2015-03-18 2021-11-23 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
WO2016183097A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
US10463753B2 (en) * 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
RS65016B1 (sr) 2016-11-16 2024-01-31 H Lundbeck As Kristalni oblik magl inhibitora
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MX393241B (es) 2016-11-16 2025-03-24 H Lundbeck As Formulaciones farmaceuticas.
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150018335A1 (en) * 2012-01-06 2015-01-15 Abide Therapeutics, Inc Carbamate compounds and of making and using same

Also Published As

Publication number Publication date
AU2017361257A1 (en) 2019-05-30
CR20190242A (es) 2019-07-09
KR20190077561A (ko) 2019-07-03
DK3541807T3 (da) 2021-12-06
LT3541807T (lt) 2021-12-27
CL2019001340A1 (es) 2019-10-04
EP3541807B1 (en) 2021-09-29
JP7042548B2 (ja) 2022-03-28
MA46866B1 (fr) 2021-11-30
KR102508739B1 (ko) 2023-03-09
TN2019000151A1 (en) 2020-10-05
PT3541807T (pt) 2021-12-09
HUE064559T2 (hu) 2024-03-28
MA46866A (fr) 2021-06-02
NZ753241A (en) 2021-06-25
ES2966939T3 (es) 2024-04-25
SMT202300494T1 (it) 2024-01-10
CN110291083B (zh) 2022-06-17
WO2018093953A1 (en) 2018-05-24
PL3541807T3 (pl) 2022-01-17
PH12019501068A1 (en) 2019-08-19
PL3964503T3 (pl) 2024-04-02
RS65016B1 (sr) 2024-01-31
NI201900053A (es) 2019-10-30
EA201991086A1 (ru) 2019-11-29
ZA201903093B (en) 2020-11-25
ES2900016T3 (es) 2022-03-15
CA3043610A1 (en) 2018-05-24
EP3964503C0 (en) 2023-11-08
RS62665B1 (sr) 2021-12-31
MA58133B1 (fr) 2024-02-29
HRP20211863T1 (hr) 2022-03-04
HRP20231697T1 (hr) 2024-03-15
SMT202100675T1 (it) 2022-01-10
EP3541807A1 (en) 2019-09-25
RU2019116689A3 (cg-RX-API-DMAC7.html) 2021-02-26
MX389459B (es) 2025-03-20
EP3964503B1 (en) 2023-11-08
US20220235037A1 (en) 2022-07-28
MY199386A (en) 2023-10-25
US20200190063A1 (en) 2020-06-18
HUE056973T2 (hu) 2022-04-28
BR112019010003A2 (pt) 2019-08-20
RU2019116689A (ru) 2020-12-17
MX2022000249A (es) 2022-02-03
SI3541807T1 (sl) 2022-01-31
JP2019537596A (ja) 2019-12-26
US11142517B2 (en) 2021-10-12
IL266548A (en) 2019-07-31
JP7350117B2 (ja) 2023-09-25
UA124585C2 (uk) 2021-10-13
CN115093382A (zh) 2022-09-23
US11993588B2 (en) 2024-05-28
CO2019005045A2 (es) 2019-05-31
ECSP19035171A (es) 2019-05-31
PE20191239A1 (es) 2019-09-16
CN110291083A (zh) 2019-09-27
JOP20190109A1 (ar) 2019-05-09
CY1124870T1 (el) 2022-11-25
DOP2019000120A (es) 2019-09-30
MX2019005767A (es) 2019-12-05
GEP20237559B (en) 2023-10-25
EP3964503A1 (en) 2022-03-09
EP3541807A4 (en) 2020-04-22
JP2022084717A (ja) 2022-06-07
JOP20190109B1 (ar) 2022-09-15

Similar Documents

Publication Publication Date Title
US11993588B2 (en) Crystalline forms of a MAGL inhibitor
RS66922B1 (sr) Kristalni oblici metil (s)‑2‑((2‑(2,6-difluoro‑4‑(metilkarbamoil)fenil)‑7-metilimidazo[1,2-a]piridin‑3-il)metil)morfolin‑4-karboksilata modulatora p2x3
HK40069310A (en) A crystalline form of a magl inhibitor
HK40069310B (en) A crystalline form of a magl inhibitor
RU2799564C2 (ru) Кристаллические формы ингибитора magl
HK40009165A (en) A crystalline form of a magl inhibitor
HK40009165B (en) A crystalline form of a magl inhibitor
AU2018325267B2 (en) Crystalline forms of compounds for preventing or treating sensory hair cell death
EA041551B1 (ru) Кристаллические формы ингибитора magl
NZ753241B2 (en) Crystalline forms of a magl inhibitor
US20240010649A1 (en) Crystalline forms of an s1p receptor modulator
US20240010654A1 (en) Crystalline forms of a tyk2 inhibitor
WO2017073738A1 (ja) フェキソフェナジンを有効成分とする錠剤

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: H. LUNDBECK A/S.

Free format text: FORMER APPLICANT(S): LUNDBECK LA JOLLA RESEARCH CENTER, INC.

Owner name: LUNDBECK LA JOLLA RESEARCH CENTER, INC.

Free format text: FORMER APPLICANT(S): ABIDE THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired